Tagrisso 80mg Tablets| Osimeritinib Uses & Side effects - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Tagrisso 80mg Tablets| Osimeritinib Uses & Side effects

Description:

Tagrisso 80mg tablet is for advanced non-small cell lung cancer with EGFR mutation positive patients, It is also used for the treatment of patients affected with advanced EGFR T792M mutation positive NSCLC, disease has advanced on or after the tyrosine kinase inhibitor treatment – PowerPoint PPT presentation

Number of Views:0

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Tagrisso 80mg Tablets| Osimeritinib Uses & Side effects


1
OSIMERITINIB 80MG TAGRISSO 80MG
MILLIONHEALTHPHARMA
2
DESCRIPTION
  • A Tagrisso 80mg tablet is containing an active
    substance known as Osimeritinib, which is
    formerly known as Mereletinib.
  • Tagrisso 80mg is considered as third generation
    medicine, which is available in tablet form.

3
(No Transcript)
4
DESCRIPTION
  • Tagrisso 80mg is an inevitable, selectively
    deviated epidermal growth factor receptor
    prohibitor, containing anti-cancer activity.
  • The pharmacological category of Tagrisso 80mg
    tablet is tyrosine kinase prohibitor.

5
INDICATION
6
  • A Tagrisso 80mg tablet is widely indicated as
    first line therapy for advanced non-small cell
    lung cancer with EGFR mutation positive patients.
  • Tagrisso 80mg tablet is also used for the
    treatment of patients affected with advanced EGFR
    T792M mutation positive NSCLC, disease has
    advanced on or after the tyrosine kinase
    inhibitor treatment.

7
MECHANISM OF ACTION
8
PROPERTIES
  •   Ingredients Bevacizumab
  •    Strength      100mg/4ml 
  •   Package      400mg of Bevacizumab containing
    vial

9
ADME PROPERTIES
  • Absorption
  • High plasma concentration time of Osimeritinib
    reaches within 6 hours
  • Distribution
  • Volume of distribution 918L
  • Human Plasma protein bound to Osimeritinib is 95

10
ADME PROPERTIES
  • Metabolism
  • The metabolism of Osimeritinib is occurs via
    oxidation.
  • The Two pharmacologically active metabolite of
    Osimeritinib are AZ7550 AZ5104
  • Excretion
  • The mean terminal half-life period 48 hours
  • Clearance value 14.3L/hr
  • 68 of metabolite is excreted in feces 14
    through urine
  • 2 of unchanged form of drug is eliminated

11
DOSAGE MANAGEMENT
12
  • The recommended dosage of Tagrisso 80mg
    tablets are, 80mg tablet should be taken as a
    single dose.
  • Tagrisso tablet should be administered with or
    without food.
  • If patient felt difficult to swallow the Tagrisso
    tablets as such, must disperse the tablet in 60ml
    of noncarbonated water and drink the solution
    immediately.
  • Tagrisso tablet do not break, crush or chew.

13
Interrupt the treatment during the conditions
like
  • Interstitial lung disease
  • QT prolongation
  • Symptomatic congestive heart failure
  • In pain management
  • Grade III or severe discontinue the Tagrisso
    tablet for 3 weeks

14
  • Grade 0 to II follow at 80mg or 40mg as a single
    dose
  • If no development in 3 weeks Discontinue the
    therapy.
  • While co administration of Tagrisso with CYP3A4
    inducers, the dosage of Tagrisso 80mg should be
    increased to 160mg as a single dose and followed
    by 80mg for 3 weeks after discontinuation of
    strong CYP3A4 inducers.

15
PRECAUTIONS
16
  • Interstitial lung disease
  • To avoid this problem, withheld or stop
    the Tagrisso 80mg tablets.

17
  • Keratitis
  • check the manifestation of keratitis regularly
    and provide supportive measures

18
  • Embryo fetal toxicity Tagrisso 80mg
    tablet required in pr
  • QTc extension
  • Do not concurrent use of Tagrisso 80mg with drug
    prolong the QTc
  • egnancy period causes fetal damage.

19
  • Cardiomyopathy
  • Periodic cardiac monitoring is assessed in this
    condition stop the therapy.

20
SIDE EFFECTS
  • The most common adverse effects occurred during
    the therapy
  • Cardiomyopathy, QT prolongation, Interstitial
    lung disease, Keratitis.
  • Other common side effect
  • Diarrhea or constipation, Hyperglycemia,
    Hypomagnesemia, Hyponatremia, Elevation of AST
    ALT, Stomatitis, Nausea, Vomiting, Rash, Nail
    toxicity, Pruritus, Dry skin, Headache, Cough,
    Dyspnea, Fatigue, Pyrexia, Loss of appetite,
    Respiratory tract infection, Lymphopenia,
    Thrombocytopenia, Anemia, Neutropenia.

21
  • PREGNANCY
  • Pregnancy category of Osimeritinib is not
    designate
  • While using Tagrisso 80mg tablet causes possible
    for fetal harm.
  • LACTATION
  • Milk feeding should not be taken during lactation
    period.
  • STORAGE
  • The Tagrisso 80mg tablet is, stored at 25C.
  • Keep the tablet carton from moisture, heat and
    light.

22
  • MISSED DOSE
  • In case of missed dose, do not take the missed
    dose and follow the regular dosing schedule.

23
CONTACT US
  • PHONE NO91-9940472902
  •  EMAIL       millionhealthpharmaceuticals_at_gmail.c
    om 
  •  WEBSITE  https//millionpharma.com/osimeritinib-
    80mg.php

24
About PowerShow.com